Calcium channel blockers: Differences between subclasses

American Journal of Cardiovascular Drugs

Volumn 7, Issue SUPPL. 1, 2007, Pages 17-23

  Frishman, William H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS LOSARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CILNIDIPINE; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; LACIDIPINE; METOPROLOL SUCCINATE; NICARDIPINE; NIFEDIPINE; PLACEBO; PRAZOSIN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNCLASSIFIED DRUG; VERAPAMIL; DIHYDROPYRIDINE;

ANGINA PECTORIS; ANKLE EDEMA; ATRIOVENTRICULAR CONDUCTION; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENDOTHELIAL DYSFUNCTION; FLUSHING; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPATHETIC TONE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VASODILATATION; DRUG EFFICACY; DRUG POTENCY; INCIDENCE; INOTROPISM; MEDICATION COMPLIANCE;

ANGINA PECTORIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 34247627986     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707010-00002     Document Type: Review

References (71)

1. Frishman WH. Current status of calcium channel blockers. Curr Probl Cardiol 1994; 19 (11): 637-88
2. Taira N. Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987 Jan 30; 59 (3): 24B-29B
3. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999 Nov 4; 341 (19): 1447-57
4. Opie LH. Pharmacological differences between calcium antagonists. Eur Heart J 1997 Jan; 18 Suppl. A: A71-9
5. Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004 Sep; 22 (9): 1641-8
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
7. ESH-ESC. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
8. Frishman WH, Sica DA. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, Sica DA, editors. Cardiovascular pharmacotherapeutics. 2nd ed. New York: McGraw-Hill, 2003: 105-130
9. Gradman AH, Frishman WH, Kaihlanen PM, et al. Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension. Am J Cardiol 1992 Dec 15; 70 (20): 1571-5
10. Thulin T, Almkvist H, Berglund L, et al. Efficacy and tolerability of felodipine ER and diltiazem SR as monotherapy in primary hypertension: a double-blind randomized study. Cardiovasc Drugs Ther 1994 Dec; 8 (6): 845-9
11. Watts RW, Wing LM. A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring. Blood Press 1998 Jan; 7 (1): 25-30
12. Cummings DM, Amadio P Jr, Nelson L, et al. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med 1991 Feb; 151 (2): 250-9
13. Flack JM, Sica DA. Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy. J Clin Hypertens (Greenwich) 2005 Apr; 7 (4 Suppl. 1): 9-14
14. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003 Jul 9; 290 (2): 199-206
15. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004 Oct 19; 141 (8): 614-27
16. Cubeddu LX, Aranda J, Singh B, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA 1986 Oct 24-31; 256 (16): 2214-21
17. Saunders E, Weir MR, Kong BW, et al. Acomparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990 Aug; 150 (8): 1707-13
18. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs singledrug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995 Feb; 8 (2): 189-92
19. Phillips RA, Kloner RA, Grimm Jr RH, et al. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens (Greenwich) 2003 Jan-Feb; 5 (1): 17-23
20. Sareli P, Radevski IV, Valtchanova ZP, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med 2001 Apr 9; 161 (7): 965-71
21. ALLHAT Study Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
22. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003 Mar 10; 163 (5): 525-41
23. Nadar S, Blann AD, Lip GY. Antihypertensive therapy and endothelial function. Curr Pharm Des 2004; 10 (29): 3607-14
24. Panza JA, Quyyumi AA, Brush Jr JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990 Jul 5; 323 (1): 22-7
25. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993 Jun; 21 (6 Pt 2): 929-33
26. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988 Jun 16; 333 (6174): 664-6
27. Taddei S, Virdis A, Ghiadoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998 Jun 9; 97 (22): 2222-9
28. Taddei S, Virdis A, Mattei P, et al. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation 1995 Nov 15; 92 (10): 2911-8
29. Lupo E, Locher R, Weisser B, et al. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 1994 Sep 30; 203 (3): 1803-8
30. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992 Jun; 70 (6): 1099-103
31. Taddei S, Virdis A, Ghiadoni L, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001 Mar; 37 (3): 943-8
32. Noronha-Dutra AA, Steen-Dutra EM, Woolf N. An antioxidant role for calcium antagonists in the prevention of adrenaline mediated myocardial and endothelial damage. Br Heart J 1991 Jun; 65 (6): 322-5
33. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003 Jun; 41 (6): 1281-6
34. Granier P, Douste-Blazy MY, Tredez P, et al. Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. Eur J Clin Pharmacol 1990; 39 Suppl. 1: S45-6
35. Magometschnigg D, Brandt D, Hofmann R, et al. Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril - a multicenter study. Int J Clin Pharmacol Ther 1997 Sep; 35 (9): 389-96
36. Schussheim AE, Diamond JA, Phillips RA. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension. Am J Cardiol 2001 Jan 1; 87 (1): 61-5
37. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997 Apr 15; 95 (8): 2007-14
38. Leenen FH, Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Am J Cardiol 1996 Jul 15; 78 (2): 203-7
39. Roul G, Germain P, Plan D, et al. Diltiazem slow-release and left-ventricular hypertrophy: a volumetric approach of left ventricular mass using magnetic resonance imaging. J Hum Hypertens 1997 Jun; 11 (6): 379-85
40. Black HR, Elliott WJ, Weber MA, et al. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension 2001 Nov; 38 (5): 1118-23
41. Takami T, Shigematsu M. Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. Clin Exp Hypertens 2003 Nov; 25 (8): 525-35
42. Bilge AK, Atilgan D, Tukek T, et al. Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. Int J Clin Pract 2005 Mar; 59 (3): 306-10
43. Agabiti-Rosei E, Trimarco B, Muiesan ML, et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005 May; 23 (5): 1091-8
44. Papademetriou V. From hypertension to heart failure. J Clin Hypertens (Greenwich) 2004 Oct; 6 (10 Suppl. 2): 14-7
45. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000 Dec 9; 356 (9246): 1955-64
46. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000 Dec 9; 356 (9246): 1949-54
47. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004 Jun 19; 363 (9426): 2049-51
48. He J, Whelton PK. Selection of initial antihypertensive drug therapy. Lancet 2000 Dec 9; 356 (9246): 1942-3
49. Frishman WH, Charlap S. Calcium-channel blockers for combined systemic hypertension and myocardial ischemia. Circulation 1987 Jun; 75 (6 Pt 2): V154-62
50. Chan PK, Heo JY, Garibian G, et al. The role of nitrates, beta blockers, and calcium antagonists in stable angina pectoris. Am Heart J 1988 Sep; 116 (3): 838-48
51. Basu SK, Kinsey CD, Miller AJ, et al. Improved efficacy and safety of controlled-release diltiazem compared to nifedipine may be related to its negative chronotropic effect. Am J Ther 2000 Jan; 7 (1): 17-22
52. Subramanian VB, Bowles MJ, Khurmi NS, et al. Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods. Acta Med Scand Suppl 1984; 681: 61-73
53. Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999 Feb 15; 83 (4): 507-14
54. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995 Jul; 26 (1): 143-9
55. Muiesan G, Agabiti-Rosei E, Romanelli G, et al. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 1986 Feb 26; 57 (7): 44D-49D
56. Lefrandt JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001 Nov; 14 (11 Pt 1): 1083-9
57. Verelan PM capsules (verapamil hydrochloride) prescribing information. Mequon (WI): Schwarz Pharma, 2006
58. Calan SR (verapamil hydrochloride) sustained-release oral caplets prescribing information. New York (NY): Pharmacia, 2003
59. Kawai C, Konishi T, Matsuyama E, et al. Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies. Circulation 1981 May; 63 (5): 1035-42
60. Kjeldsen SE, Syvertsen JO, Hedner T. Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases. Blood Press 1996 Sep; 5 (5): 260-3
61. Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol 2004 Jul 7; 44 (1): 105-8
62. Cardizem SR (diltiazem HCL) prescribing information. Morrisville (NC): Biovail Pharmaceuticals, Inc., 2001
63. Abernethy DR, Schwartz JB, Todd EL, et al. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. Ann Intern Med 1986 Sep; 105 (3): 329-36
64. Schwartz JB, Abernethy DR. Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension. Am J Cardiol 1987 May 1; 59 (12): 1111-7
65. R&D Insight Proprietary Database. Auckland: Wolters Kluwer Health | Adis, Pharma Solutions Division, 2006
66. Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995 Nov; 35 (11): 1060-6
67. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec 3; 290 (21): 2805-16
68. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 2004 Nov; 44 (5): 637-42
69. Jamerson K, Champion A, Zhou Q, et al. Verapamil- and atenolol-based strategies are equally effective in black patients with hypertension and coronary artery disease: a subanalysis of the International VErapamil SRTrandolapril study (INVEST) [abstract no. P286]. Am J Hypertens 2005; 18 (5 Suppl.): A109
70. Cooper-DeHoff RM, Kolloch R, Messerli FH, et al. Blood pressure control, angina episodes, and cardiovascular outcomes in patients with ischemia: the International Verapamil/Trandolapril Study [abstract no. 1085-197 plus poster]. J Am Coll Cardiol 2004; 43 (5 Suppl. A): 483A
71. Frishman WH, Hainer JW, Sugg J for the M-FACT Study Group. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release. Am J Hypertens 2006; 19 (4): 388-95